Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

Steven Robert Alberts,Stephen N. Thibodeau,D. J. Sargent,Michelle R. Mahoney,Frank A. Sinicrope,Anthony F. Shields,Emily Y. Y. Chan,R. M. Goldberg,Sharlene Gill,Morton S. Kahlenberg,James T. Quesenberry,Thomas Christopher Smyrk,A. Grothey,Suresh Nair

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

2011

Steven Robert Alberts
Stephen N. Thibodeau
D. J. Sargent
Michelle R. Mahoney
Frank A. Sinicrope
Anthony F. Shields
Emily Y. Y. Chan
R. M. Goldberg
Sharlene Gill
Morton S. Kahlenberg
James T. Quesenberry
Thomas Christopher Smyrk
A. Grothey
Suresh Nair

3607 Background: Mutation (mut) of KRAS and BRAF negatively influence response to Cmab in metastatic colorectal cancer with the possible exception of KRAS Gly13Asp (JAMA 304:1812). Incidence of ras...

Keywords:

Cetuximab
Rash
KRAS
Stage III Colon Cancer
Disease
Oncology
Internal medicine
Medicine
mutational status
disease free survival
Colorectal cancer
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations